Valuation: Synta Pharmaceuticals Corp.

Market Cap 9.93B 9B 8.32B 7.51B 14.15B 936B 14.65B 99.96B 39.64B 500B 37.26B 36.47B 1,587B P/E 2026 *
-254x
P/E 2027 * 60.9x
Enterprise Value 9.29B 8.42B 7.79B 7.03B 13.24B 876B 13.71B 93.57B 37.1B 468B 34.87B 34.13B 1,486B EV / Sales 2026 *
5.86x
EV / Sales 2027 * 4.11x
Free-Float
94.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Director/Board Member 74 2016-06-30
Director/Board Member 68 2016-08-10
Director/Board Member 64 2019-06-26
Change 5-day change 1-year change 3-year change Capi.($)
-2.69%-0.48%+53.97%+66.82% 66.33B
-0.92%+7.67%+12.64%+93.22% 60.62B
0.00%+0.39%+22.34%+89.58% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
-2.32%-2.24%+76.50%+56.02% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average -0.61%+0.05%+36.79%+176.56% 45B
Weighted average by Cap. -0.83%+0.20%+36.63%+152.23%

Financials

2026 *2027 *
Net sales 1.59B 1.44B 1.33B 1.2B 2.26B 149B 2.34B 15.96B 6.33B 79.84B 5.95B 5.82B 253B 2.19B 1.98B 1.83B 1.65B 3.11B 206B 3.22B 22B 8.73B 110B 8.2B 8.03B 349B
Net income -48.18M -43.66M -40.39M -36.44M -68.67M -4.54B -71.09M -485M -192M -2.43B -181M -177M -7.7B 216M 196M 181M 163M 308M 20.35B 318M 2.17B 862M 10.87B 810M 793M 34.5B
Net Debt -635M -575M -532M -480M -905M -59.87B -937M -6.39B -2.54B -31.98B -2.38B -2.33B -102B -957M -867M -802M -723M -1.36B -90.2B -1.41B -9.63B -3.82B -48.18B -3.59B -3.51B -153B
Logo Synta Pharmaceuticals Corp.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Synta Pharmaceuticals Corp.